Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: J Geriatr Oncol. 2016 Feb 23;7(3):176–186. doi: 10.1016/j.jgo.2016.01.011

Figure 3. Exploratory analysis of treatment effect heterogeneity by age at diagnosis comparing postoperative 5-FU/capecitabine alone versus no postoperative chemotherapy and all-cause mortality.

Figure 3

The solid black line denotes the adjusted hazard ratio estimated using age-stratified subgroups and a one-year moving window, resulting in 25 estimates. All estimates used 5-year age groupings (e.g., 71-75 years, age midpoint=73 years), when possible. The estimates for age 66 and 67 used one and three-year age groups, respectively. Estimates for ages beyond 90 years were not calculated, as data was sparse. The adjusted hazard ratios are plotted at the midpoint of each age group along with robust 95% confidence intervals (plotted on the log scale).